Unknown

Dataset Information

0

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.


ABSTRACT: INTRODUCTION:The long-term prognosis of HIV-2-infected patients receiving antiretroviral therapy (ART) is still challenging, due to the intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and the suboptimal response to some protease inhibitors (PI). The objective was to describe the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses. METHODS:A clinic-based cohort of HIV-2-patients experiencing virologic failure, with at least one drug resistance mutation was followed from January 2012 to August 2017 in Côte d'Ivoire. Follow-up data included death, lost to follow-up (LTFU), immuno-virological responses. The Kaplan-Meier curve was used to estimate survival rates. RESULTS:A total of 31 HIV-2 patients with virologic failure and with at least one drug resistance mutation were included. Two-third of them were men, 28(90.3%) were on PI-based ART-regimen at enrolment and the median age was 50 years (IQR = 46-54). The median baseline CD4 count and viral load were 456 cells/mm3 and 3.7 log10 c/mL respectively, and the participants have been followed-up in median 57 months (IQR = 24-60). During this period, 21 (67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an integrase inhibitor-based regimen respectively. A total of 10(32.3%) patients died and 4(12.9%) were LTFU. The 36 and 60-months survival rates were 68.5% and 64.9%, respectively. Among the 17 patients remaining in care, six(35.3%) had an undetectable viral load (<50 c/mL) and for the 11 others, the viral load ranged from 2.8 to 5.6 log10 c/mL. Twelve patients were receiving lopinavir at the time of first genotype, five(42%) had a genotypic susceptibility score (GSS) ?1 and 4(33%) a GSS >2. CONCLUSIONS:The 36-months survival rate among ART-experienced HIV-2 patients with drug-resistant viruses is below 70%,lower than in HIV-1. There is urgent need to improve access to second-line ART for patients living with HIV-2 in West Africa.

SUBMITTER: Tchounga BK 

PROVIDER: S-EPMC7406077 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.

Tchounga Boris K BK   Charpentier Charlotte C   Coffie Patrick A PA   Dabis François F   Descamps Diane D   Eholie Serge P SP   Ekouevi Didier K DK  

PloS one 20200805 8


<h4>Introduction</h4>The long-term prognosis of HIV-2-infected patients receiving antiretroviral therapy (ART) is still challenging, due to the intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and the suboptimal response to some protease inhibitors (PI). The objective was to describe the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses.<h4>Methods</h4>A clinic-based cohort of HIV-2-patients experiencing virologic failure, with at least one dru  ...[more]

Similar Datasets

| S-EPMC6746366 | biostudies-literature
| S-EPMC7838880 | biostudies-literature
| S-EPMC10903046 | biostudies-literature
| S-EPMC9145614 | biostudies-literature
| S-EPMC6339280 | biostudies-literature
| S-EPMC3104241 | biostudies-other
| S-EPMC6468708 | biostudies-literature
| S-EPMC6720463 | biostudies-literature
| S-EPMC5998745 | biostudies-literature
| S-EPMC2775848 | biostudies-literature